ID | 1288 |
Name of the vaccine | V441 |
Microbe | Bacteria |
Disease name | Pertussis (Whooping Cough) |
Name of bacteria | Bordetella pertussis |
Type of vaccine | Conjugate |
Nucleic acid content | DNA |
Age | 6 to 8 weeks |
Description of the vaccine | Diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B (recombinant), & Haemophilus influenza type b conjugate vaccine. |
Name of the manufacturer | Merck Sharp & Dohme Corp. |
Name of the manufacturing country | NA |
Year of manufacture | 2003 |
Clinical Phase status | Clinical - Phase 3 |
Bacterial strain | Gram-negative coccobacillus. |
Efficacy | NA |
Vaccine formulation | NA |
Dosage | NA |
Mechanism of action | NA |
Route of administration | NA |
Indications | NA |
Export | NA |
Approval | NA |
Adjuvant | NA |
Repurposing | For diphtheria, tetanus, hepatitis B and poliomyelitis. |
Side effects of vaccine | NA |
Post vaccination | NA |
Dose type | NA |
Interspecies transfer | NA |
PubMed identifier | NA |
Clinical trial number | NCT00092469 |
Reference | NA |
Other name | NA |
Additional Links | NA
|